Business
SCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences
JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and
About this update from Scynexis, Inc.
[{"type":"text","content":"JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced participation in three women’s health conferences in April. “As the creator of the first oral treatment for vaginal yeast infection approved in the Unites States in more than 20 years, our scientific teams are extremely proud to be at the forefront of research and development for new groundbreaking treatments in the underserved area of women’s health,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, “We look forward to having an opportunity during these meetings to join medical colleagues from around the country to discuss and learn details about important advancements in the field.” Conferences: American College of Osteopathic Obstetricians and Gynecologists (ACOOG) 89th Annual ConferenceTheme: Moving Forward – Debates and Directions in Women’s HealthDate: April 3-8, 2022Location: San AntonioEvent Information National Black Nurse Practitioner Association (NBNPA) 3rd Annual Educational Conference Theme: Diversity and Inclusion in Healthcare – Its Impact on Patient Care Date: April 29-30, 2022Location: HoustonEvent Information Ms. Medicine Women’s Health Matters Conference Theme: What’s New in 2022 – CME EventDate: April 28-30, 2022Location: Ft. Lauderdale, Fla.Event Information About BREXAFEMME® (ibrexafungerp tablets) BREXAFEMME is a novel oral antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. Its mechanism of action, glucan synthase inhibition, is fungicidal against Candida species, meaning it kills fungal cells. The New Drug Application (NDA) for BREXAFEMME was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. The NDA was supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated efficacy and a favorable tolerability profile in women with VVC. BREXAFEMME represents the first approved drug in a new antifungal class in over 20 years and is the first and only treatment for vaginal yeast infections which is both oral and non-azole. INDICATION BREXAFEMME is a triterp...